One cancer drug turned down after many years of research, but the company plans an appeal. The FDA continues to ask for substantial documentation in the hopes of better decision. Refusals don't help the cause when it comes to investors and 
the potential for continued research.
Something about biotech and Pharma these days remind me of my ex brother in law from a number of years back who worked in the lab of a refinery. They tested the crude oil coming in to add the correct amounts of additives, as each lot was not the same, and the drug business model in some ways sure resembles some of the processes here and hopefully for the good, keep reworking the process until we get it right, although much more stringent requirements by comparison. BD
Introgen (Nasdaq: INGN) says the FDA has notified the company that its application for its Advexin head and neck cancer treatment was not complete and would therefore not be filed at this time. The Austin-based company says it will appeal the decision and is exploring its options.
Shares of Introgen fell to 60 cents in early trading Tuesday, down more than 35 percent from the stock’s Friday closing price of 93 cents. Introgen has traded within a 52-week range of 80 cents and $4.85..
FDA refuses Introgen application; stock in freefall - Austin Business Journal:
0 comments :
Post a Comment